- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Di | ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs | 1 | GlobeNewswire (USA) | ||
| 22.10. | ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases | 1 | GlobeNewswire (USA) | ||
| 17.10. | ZyVersa macht Fortschritte bei Medikament gegen Fettleibigkeit mit wichtigen Meilensteinen in Aussicht | 2 | Investing.com Deutsch | ||
| 17.10. | ZyVersa advances obesity drug with key milestones ahead | 5 | Investing.com | ||
| 17.10. | ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months | 54 | GlobeNewswire (Europe) | Lead indication for ZyVersa's Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications. WESTON, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA,... ► Artikel lesen | |
| 15.10. | ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors | 1 | GlobeNewswire (USA) | ||
| 07.10. | ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications | 3 | GlobeNewswire (USA) | ||
| 16.09. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.09. | ZVSA-Aktie erreicht 52-Wochen-Tief bei 2,4 $ inmitten starken Jahresrückgangs | - | Investing.com Deutsch | ||
| 12.09. | ZVSA stock touches 52-week low at $2.4 amid sharp annual decline | 1 | Investing.com | ||
| 03.09. | ZyVersa Therapeutics files for mixed shelf offering | 1 | Seeking Alpha | ||
| 09.08. | ZyVersa Therapeutics GAAP EPS of -$3.31 beats by $0.44 | 2 | Seeking Alpha | ||
| 09.08. | ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update | 1.351 | GlobeNewswire (Europe) | KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease on track to begin H2-2024.Obesity with related metabolic complications selected... ► Artikel lesen | |
| 09.08. | ZyVersa Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.08. | ZVSA Stock Touches 52-Week Low at $3.01 Amid Market Challenges | 1 | Investing.com | ||
| 07.08. | ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation | 1 | GlobeNewswire (USA) | ||
| 01.08. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.07. | ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults | 1 | GlobeNewswire (USA) | ||
| 25.07. | ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100 | 2 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,100 | +13,37 % | Evotec Aktie: Wochen der Wahrheit? | Bei der Evotec Aktie haben am Donnerstag und Freitag zum einen Gewinnmitnahmen nach dem jüngsten Kursanstieg das Bild geprägt. Aber - zumindest am Donnerstag - blieben zudem Rückkäufe der Evotec Aktie... ► Artikel lesen | |
| QIAGEN | 40,170 | +1,11 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
| VIKING THERAPEUTICS | 59,00 | -13,39 % | AKTIONÄR-Depotwert Gubra: Bald wie Viking Therapeutics? | Die Aktie von Viking Therapeutics hat in der Vorwoche massive Kursgewinne verzeichnet. Vor allem die Aussicht auf weiteren Studiendaten zum Adipositas-Hoffnungsträger VK2735 Anfang November sowie die... ► Artikel lesen | |
| BIONTECH | 102,20 | -0,20 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,280 | +0,18 % | ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. | ||
| DISC MEDICINE | 59,41 | +28,18 % | Disc Medicine Inc: Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval | Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,55 | -0,22 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,080 | +8,02 % | Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 33,040 | -0,24 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,990 | +6,86 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
| DYNE THERAPEUTICS | 28,870 | +0,21 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| ARCELLX | 87,83 | +2,59 % | Arcellx (ACLX) Surged in Q3. Here's Why | ||
| BEAM THERAPEUTICS | 24,760 | +8,60 % | Beam Therapeutics' Earnings: A Preview | ||
| RECURSION PHARMACEUTICALS | 6,665 | +3,57 % | Peering Into Recursion Pharmaceuticals' Recent Short Interest | ||
| NEUMORA THERAPEUTICS | 11,690 | +3,73 % | Neumora Therapeutics, Inc.: Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 |
Das Unternehmen ZYVERSA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,09 % bei einem Aktienkurs von 1,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZYVERSA THERAPEUTICS INC finden Sie auf Wallstreet Online.
